Main content Nucleoside Reverse Transcriptase Inhibitors (NRTIs) for Chronic Hepatitis B

    Nucleoside Reverse Transcriptase Inhibitors (NRTIs) for Chronic Hepatitis B



    References

    Citations

    1. Lok SFL, McMahon BJ (2009). Chronic Hepatitis B: Update 2009. Available online: http://www.aasld.org/practiceguidelines/Documents/Bookmarked%20Practice%20Guidelines/Chronic_Hep_B_Update_2009%208_24_2009.pdf.

    2. Hadziyannis SJ, et al. (2003). Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. New England Journal of Medicine, 348(9): 800–807.

    3. Chang T-T, et al. (2006). A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. New England Journal of Medicine, 354(10): 1001–1010.

    4. Lai C-L, et al. (2006). Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. New England Journal of Medicine, 354(10): 1011–1020.

    5. Leung N, et al. (2009). Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir. Hepatology, 49(1): 72–79.

    6. Hadziyannis, SJ, et al. (2005). Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. New England Journal of Medicine, 352(26): 2673–2681.

    7. Reynaud L, et al. (2009). Tenofovir and its potential in the treatment of hepatitis B virus. Therapeutics and Clinical Risk Management, 5(1): 177–185.

    8. Hann H-W, et al. (2008). Tenofovir (TDF) has stronger antiviral effect than adefovir (ADV) against lamivudine (LAM)-resistant hepatitis B virus (HBV). Hepatology International, 2(2): 244–249.

    9. Chan HLY, et al. (2005). A randomized, controlled trial of combination therapy for chronic hepatitis B: Comparing pegylated interferon alfa-2b and lamivudine with lamivudine alone. Annals of Internal Medicine, 142(4): 240–250.

    10. Janssen, H (2005). Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: A randomised trial. Lancet, 365(9454): 123–129.




    By: Reference Healthwise Staff Last Revised: October 29, 2012
    Medical Review: Reference Kathleen Romito, MD - Family Medicine
    Reference W. Thomas London, MD - Hepatology


    This information does not replace the advice of a doctor. Healthwise, Incorporated disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Reference Terms of Use. Reference How this information was developed to help you make better health decisions.


    Topic Contents